We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Thermo Fisher Presents Cascadion SM Clinical Analyzer and LC-MS IVD Medical Devices at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 12 Apr 2022
Print article
Image: Cascadion SM Clinical Analyzer (Photo courtesy of Thermo Fisher Scientific)
Image: Cascadion SM Clinical Analyzer (Photo courtesy of Thermo Fisher Scientific)

Thermo Fisher Scientific (Waltham, MA, USA) presented its Cascadion SM clinical analyzer and range of LC-MS IVD medical devices at EUROMEDLAB 2022.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is considered the gold standard among vitamin D testing methods, but the technique has traditionally relied on sophisticated technology requiring specialized knowledge. The Cascadion SM clinical analyzer, equipped with a built-in 25-hydroxy vitamin D assay, automatically analyzes vitamin D2 and D3 in blood samples directly from qualified primary blood collection tubes, without the need for extensive technical expertise. Incorporating sample processing, LC separation and MS detection capabilities in a single solution, the Cascadion system is fully automated and enables load-up and walkaway sample management, eliminating the need for multiple connected components. The system offers end-to-end automation that is easy to use by any qualified laboratory personnel with minimal training, thus streamlining and optimizing the analytical process. The clinical analyzer is designed to simplify and accelerate the implementation of LC-MS/MS into routine clinical workflows.

Also on display at EUROMEDLAB 2022 was the Thermo Fisher family of LC-MS instruments for in vitro diagnostics that provides clinical labs with consistent reliable results, faster. These comprehensive, reliable LC-MS platform solutions offer greater flexibility than immunoassays, facilitate cost savings and enable clinical laboratories to achieve their productivity goals, while ensuring confidence in results of laboratory developed tests (LDTs). Thermo Fisher demonstrated the Vanquish MD HPLC which is the ideal chromatographic separations system for laboratories where analyte resolution is critical, alongside the TSQ Quantis MD Series mass spectrometer that is used by clinical diagnostic laboratories to meet routine requirements for laboratory tests. In addition, Thermo Fisher showcased the TSQ Altis MD Series mass spectrometer that is used by clinical diagnostic laboratories to address challenging analyte requirements for LDTs.

Related Links:
Thermo Fisher Scientific

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more